CTSI: Collaborative and Novel Technologies (CNTR)
To accelerate clinically relevant discovery and translation into more effective diagnostic, therapeutic and preventative strategies for chronic diseases, it is critical to apply optimal technologies to the most important clinical and translational problems. Indeed, interdisciplinary interactions of CTSI investigators have developed and applied enabling technologies that have resulted in important scientific advances. The Univeristy of Maryland and its partner institutions are fortunate to have a substantial repertoire of technologies that CTSI investigators use to make seminal discoveries.
The objective of the Collaborative and Novel Technologies Program is to accelerate wide application of these productive technologies and to identify, develop, and disseminate to CTSI investigators new and emerging enabling technologies to accelerate high impact discovery, translational and clinical research to improved patient care and community health.
Focusing on technologies with applications across a broad range of clinical and translational research, the CNTP will provide a unifying infrastructure to systematically identify, implement, optimize and disseminate selected enabling technologies for clinical and translational research across the UM CTSI. The CNTP will choose the technologies to advance via a rigorous review process, based on novelty, potential to advance clinical and translational science, and utility to UM CTSI investigators. Selected enabling technologies will be developed into existing CTSI core resources and translational research pipelines, in order to technologically enable many future seminal discoveries and speed their translation to patient health impact.
|Curt Civin, Director of the Center for Stem Cell Biology & Regenerative Medicine,
Associate Dean for Research
|David Weber, Professor of Biochemistry & Molecular Biology, Director of the UM Center for Biomolecular Therapeutics (CBT),Associate Director of the Institute of Bioscience and Biotechnology Research (IBBR), Co-leader of the Greenebaum Cancer Center’s (GCC) Program in Molecular and Strutural Biology. Director of the GCC Structural Biology Shared Service
|William E. Bentley, PhD,
Robert E. Fischell Distinguished Professor ,
Founding Chair of the Fischell Department of Bioengineering